Zacks Investment Research
30 Sept 2026, 15:46 UTC · 1h ago
Verdict
Headline takes no side. We score BSX +0.40 across four claims — moderately bullish.
+0.40moderately bullish
More positive than 68% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
Boston Scientific's Urology business full-year growth guidance is now flat to low-single digits.
Priced inanalysis of Q2 results reported earlier
So whatThe guidance cut reflects a slower-than-expected recovery in sacral neuromodulation that will drag on FY2026 EPS.
More negative than 84% of claims this week
The company plans three key launches for its core stone portfolio over the next two to three quarters.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inanalysis of Q2 results reported earlier
So whatThese product fills target specific portfolio gaps to drive a return to market growth by FY2027.
More positive than 67% of claims this week
Neuromodulation sales grew 12% in the second quarter of 2026.
Priced inanalysis of Q2 results reported earlier
More positive than 55% of claims this week
Endoscopy sales grew 7% year over year in the second quarter of 2026.
Priced inanalysis of Q2 results reported earlier
More positive than 46% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
−0.2%
Price flat so far
$43.78 vs $43.88 close before publication (Sep 29) · not market-adjusted
BSX chart →
